How does ketoconazole shampoo (Nizoral) treat dandruff?

How does ketoconazole shampoo treat dandruff?

Ketoconazole is an antifungal medicine. Its shampoo is used for conditions such as dandruff and seborrhoeic dermatitis, where yeast on the skin can contribute to symptoms. It is not a treatment for every itchy or flaky scalp: persistent symptoms, broken skin or an uncertain diagnosis need a pharmacist or clinician's assessment.

Shampoo, cream and oral tablets have different uses and risks. A familiar brand name such as Nizoral does not establish that every formulation is suitable or available in your country.

Shampoo and cream serve different purposes

UK NHS guidance describes ketoconazole shampoo for scalp conditions and, in some cases, pityriasis versicolor, a fungal skin condition. Cream is applied to affected skin for appropriate fungal infections. The application schedule depends on the diagnosis and formulation.

For dandruff or seborrhoeic dermatitis, the cited UK guidance describes shampoo twice weekly for two to four weeks, followed by less frequent use if needed. Its instructions are to wet the area, lather the shampoo, leave it for three to five minutes, then rinse. That is one contact period, not a separate massage period followed by another equal waiting period.

These are examples from UK guidance, not instructions for every product. Follow the leaflet on your own pack or the directions from a pharmacist. Avoid the eyes, and do not use more often to accelerate results.

Side effects and when to seek advice

Local irritation can occur. Stop and seek advice if treatment causes a significant reaction; swelling or difficulty breathing needs emergency care. Ask a pharmacist or clinician if symptoms worsen or do not improve within the recommended course.

Bring the actual pack to the consultation. Tell the professional about other scalp treatments, allergies, pregnancy or breastfeeding so advice matches the product you will use.

Oral antifungal ketoconazole was suspended in the EU

In 2013, EU authorisations for oral ketoconazole used to treat fungal infections were suspended because of liver-injury risks. This is not simply a restriction reserving oral tablets for difficult skin infections. EMA stated that topical cream and shampoo could continue because their absorption into the body is very low.

There is a separate oral medicine, Ketoconazole Esteve, formerly Ketoconazole HRA, authorised for Cushing's syndrome under specialist supervision. That endocrine indication does not reinstate oral ketoconazole as a routine antifungal option.

What to check before buying

Check the local product's strength, indication, instructions and supply status with a licensed pharmacy. EU regulatory information does not prove that a particular shampoo is sold without prescription, stocked or available through any specific platform everywhere in Europe.

If the diagnosis is uncertain, asking which antifungal fits it is more useful than choosing a stronger product or switching to tablets yourself.

Information and clinical decisions

This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.

Further reading: treatment information.

Read about online consultations and their limits. Service information must not delay urgent local care.

Sources

1. NHS: using ketoconazole — UK shampoo and cream instructions, condition-specific schedules and a single three-to-five-minute shampoo contact period.
2. EMA: oral antifungal ketoconazole referral — 2013 suspension of oral antifungal authorisations; topical formulations were not affected.
3. EMA: Ketoconazole Esteve — Separate oral authorisation for Cushing's syndrome, not a general antifungal indication.
4. NHS: ketoconazole adverse effects — Topical irritation and emergency action for a serious allergic reaction.

See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.